Cargando…

Visual Detection of Human Antibodies Using Sugar Chain-Immobilized Fluorescent Nanoparticles: Application as a Point of Care Diagnostic Tool for Guillain-Barré Syndrome

Sugar chain binding antibodies have gained substantial attention as biomarkers due to their crucial roles in various disorders. In this study, we developed simple and quick detection method of anti-sugar chain antibodies in sera using our previously developed sugar chain-immobilized fluorescent nano...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinchi, Hiroyuki, Yuki, Nobuhiro, Ishida, Hideharu, Hirata, Koichi, Wakao, Masahiro, Suda, Yasuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574945/
https://www.ncbi.nlm.nih.gov/pubmed/26378448
http://dx.doi.org/10.1371/journal.pone.0137966
_version_ 1782390695467679744
author Shinchi, Hiroyuki
Yuki, Nobuhiro
Ishida, Hideharu
Hirata, Koichi
Wakao, Masahiro
Suda, Yasuo
author_facet Shinchi, Hiroyuki
Yuki, Nobuhiro
Ishida, Hideharu
Hirata, Koichi
Wakao, Masahiro
Suda, Yasuo
author_sort Shinchi, Hiroyuki
collection PubMed
description Sugar chain binding antibodies have gained substantial attention as biomarkers due to their crucial roles in various disorders. In this study, we developed simple and quick detection method of anti-sugar chain antibodies in sera using our previously developed sugar chain-immobilized fluorescent nanoparticles (SFNPs) for the point-of-care diagnostics. Sugar chain structure on SFNPs was modified with the sugar moieties of the GM1 ganglioside via our original linker molecule to detect anti-GM1 antibodies. The structures and densities of the sugar moieties immobilized on the nanoparticles were evaluated in detail using lectins and sera containing anti-GM1 antibodies from patients with Guillain-Barré syndrome, a neurological disorder, as an example of disease involving anti-sugar chain antibodies. When optimized SFNPs were added to sera from patients with Guillain-Barré syndrome, fluorescent aggregates were able to visually detect under UV light in three hours. The sensitivity of the detection method was equivalent to that of the current ELISA method used for the diagnosis of Guillain-Barré syndrome. These results suggest that our method using SFNPs is suitable for the point-of-care diagnostics of diseases involving anti-sugar chain antibodies.
format Online
Article
Text
id pubmed-4574945
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-45749452015-09-25 Visual Detection of Human Antibodies Using Sugar Chain-Immobilized Fluorescent Nanoparticles: Application as a Point of Care Diagnostic Tool for Guillain-Barré Syndrome Shinchi, Hiroyuki Yuki, Nobuhiro Ishida, Hideharu Hirata, Koichi Wakao, Masahiro Suda, Yasuo PLoS One Research Article Sugar chain binding antibodies have gained substantial attention as biomarkers due to their crucial roles in various disorders. In this study, we developed simple and quick detection method of anti-sugar chain antibodies in sera using our previously developed sugar chain-immobilized fluorescent nanoparticles (SFNPs) for the point-of-care diagnostics. Sugar chain structure on SFNPs was modified with the sugar moieties of the GM1 ganglioside via our original linker molecule to detect anti-GM1 antibodies. The structures and densities of the sugar moieties immobilized on the nanoparticles were evaluated in detail using lectins and sera containing anti-GM1 antibodies from patients with Guillain-Barré syndrome, a neurological disorder, as an example of disease involving anti-sugar chain antibodies. When optimized SFNPs were added to sera from patients with Guillain-Barré syndrome, fluorescent aggregates were able to visually detect under UV light in three hours. The sensitivity of the detection method was equivalent to that of the current ELISA method used for the diagnosis of Guillain-Barré syndrome. These results suggest that our method using SFNPs is suitable for the point-of-care diagnostics of diseases involving anti-sugar chain antibodies. Public Library of Science 2015-09-17 /pmc/articles/PMC4574945/ /pubmed/26378448 http://dx.doi.org/10.1371/journal.pone.0137966 Text en © 2015 Shinchi et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Shinchi, Hiroyuki
Yuki, Nobuhiro
Ishida, Hideharu
Hirata, Koichi
Wakao, Masahiro
Suda, Yasuo
Visual Detection of Human Antibodies Using Sugar Chain-Immobilized Fluorescent Nanoparticles: Application as a Point of Care Diagnostic Tool for Guillain-Barré Syndrome
title Visual Detection of Human Antibodies Using Sugar Chain-Immobilized Fluorescent Nanoparticles: Application as a Point of Care Diagnostic Tool for Guillain-Barré Syndrome
title_full Visual Detection of Human Antibodies Using Sugar Chain-Immobilized Fluorescent Nanoparticles: Application as a Point of Care Diagnostic Tool for Guillain-Barré Syndrome
title_fullStr Visual Detection of Human Antibodies Using Sugar Chain-Immobilized Fluorescent Nanoparticles: Application as a Point of Care Diagnostic Tool for Guillain-Barré Syndrome
title_full_unstemmed Visual Detection of Human Antibodies Using Sugar Chain-Immobilized Fluorescent Nanoparticles: Application as a Point of Care Diagnostic Tool for Guillain-Barré Syndrome
title_short Visual Detection of Human Antibodies Using Sugar Chain-Immobilized Fluorescent Nanoparticles: Application as a Point of Care Diagnostic Tool for Guillain-Barré Syndrome
title_sort visual detection of human antibodies using sugar chain-immobilized fluorescent nanoparticles: application as a point of care diagnostic tool for guillain-barré syndrome
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4574945/
https://www.ncbi.nlm.nih.gov/pubmed/26378448
http://dx.doi.org/10.1371/journal.pone.0137966
work_keys_str_mv AT shinchihiroyuki visualdetectionofhumanantibodiesusingsugarchainimmobilizedfluorescentnanoparticlesapplicationasapointofcarediagnostictoolforguillainbarresyndrome
AT yukinobuhiro visualdetectionofhumanantibodiesusingsugarchainimmobilizedfluorescentnanoparticlesapplicationasapointofcarediagnostictoolforguillainbarresyndrome
AT ishidahideharu visualdetectionofhumanantibodiesusingsugarchainimmobilizedfluorescentnanoparticlesapplicationasapointofcarediagnostictoolforguillainbarresyndrome
AT hiratakoichi visualdetectionofhumanantibodiesusingsugarchainimmobilizedfluorescentnanoparticlesapplicationasapointofcarediagnostictoolforguillainbarresyndrome
AT wakaomasahiro visualdetectionofhumanantibodiesusingsugarchainimmobilizedfluorescentnanoparticlesapplicationasapointofcarediagnostictoolforguillainbarresyndrome
AT sudayasuo visualdetectionofhumanantibodiesusingsugarchainimmobilizedfluorescentnanoparticlesapplicationasapointofcarediagnostictoolforguillainbarresyndrome